Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Global prevalence of classic phenylketonuria based on Neonatal Screening Program Data: systematic review and meta-analysis

  • Shoraka, Hamid Reza (Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences) ;
  • Haghdoost, Ali Akbar (HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences) ;
  • Baneshi, Mohammad Reza (Modeling in health research center, Institute for futures studies in health, Kerman University of medical sciences) ;
  • Bagherinezhad, Zohre (Department of Medical Library and Information Science, Kerman University of Medical Sciences) ;
  • Zolala, Farzaneh (Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences)
  • 투고 : 2019.05.11
  • 심사 : 2019.10.04
  • 발행 : 2020.02.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Phenylketonuria is a disease caused by congenital defects in phenylalanine metabolism that leads to irreversible nerve cell damage. However, its detection in the early days of life can reduce its severity. Thus, many countries have started disease screening programs for neonates. The present study aimed to determine the worldwide prevalence of classic phenylketonuria using the data of neonatal screening studies.The PubMed, Web of Sciences, Sciences Direct, ProQuest, and Scopus databases were searched for related articles. Article quality was evaluated using the Joanna Briggs Institute Critical Appraisal Evaluation Checklist. A random effect was used to calculate the pooled prevalence, and a phenylketonuria prevalence per 100,000 neonates was reported. A total of 53 studies with 119,152,905 participants conducted in 1964-2017 were included in this systematic review. The highest prevalence (38.13) was reported in Turkey, while the lowest (0.3) in Thailand. A total of 46 studies were entered into the meta-analysis for pooled prevalence estimation. The overall worldwide prevalence of the disease is 6.002 per 100,000 neonates (95% confidence interval, 5.07-6.93). The meta-regression test showed high heterogeneity in the worldwide disease prevalence (I2=99%). Heterogeneity in the worldwide prevalence of phenylketonuria is high, possibly due to differences in factors affecting the disease, such as consanguineous marriages and genetic reserves in different countries, study performance, diagnostic tests, cutoff points, and sample size.

키워드

참고문헌

  1. Motamedi N, Goodarzi E, Pordanjani SR, Valizadeh R, Moradi Y, Sohrabivafa M, et al. Incidence of phenylketonuria in Lorestan province, West of Iran (2006- 2016). Int J Pediatr 2017;5:4713-21.
  2. Smon A, Groselj U, Zerjav Tansek M, Bicek A, Oblak A, Zupancic M, et al. Newborn Screening in Slovenia. Zdr Varst 2015;54:86-90.
  3. Souza CAA, Alves MRA, Soares RDL, Kanufre VC, Rodrigues VM, Norton RC, et al. BH(4) deficiency identified in a neonatal screening program for hyperphenylalaninemia. J Pediatr (Rio J) 2018;94:170-6. https://doi.org/10.1016/s0022-3476(79)80405-9
  4. Morovatdar N, Aval SB, Yazdi SMRH, Norouzi F, Mina T. The epidemiological and clinical study of Phenylketonuria (PKU) patients in Khorasan, North-eastern Iran. Iran J Neonatol 2015;6:18-22.
  5. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010;376:1417-27. https://doi.org/10.1016/S0140-6736(10)60961-0
  6. Mahmoud IG, Moneem MA, Mehany DA. Epidemiological study of neurometabolic diseases diagnosed at Cairo University Children Hospital: a two years outcome. Eur J Paediatr Neurol 2015;19(Suppl1):S121. https://doi.org/10.1016/S1090-3798(15)30410-4
  7. Liu J, Hoppman N, O'Connell JR, Wang H, Streeten EA, McLenithan JC, et al. A functional haplotype in EIF2AK3, an ER stress sensor, is associated with lower bone mineral density. J Bone Miner Res 2012;27:331-41. https://doi.org/10.1002/jbmr.549
  8. Kitagawa T. Neonatal mass-screening for inborn errors of metabolism in Japan. Pediatr Int 1982;24:83-90. https://doi.org/10.1111/j.1442-200X.1980.tb00485.x
  9. Karamifar H, Ordoei M, Karamizadeh Z, Amirhakimi GH. Incidence of neonatal hyperphenylalaninemia in fars province, South iran. Iran J Pediatr 2010;20:216-20.
  10. Botler J, Camacho LA, Cruz MM. Phenylketonuria, congenital hypothyroidism and haemoglobinopathies: public health issues for a Brazilian newborn screening program. Cad Saude Publica 2012;28:1623-31. https://doi.org/10.1590/S0102-311X2012000900002
  11. Dluholucky S, Knapkova M. Newborn screening in Slovakia - from 1985 till today. Acta Facultatis Pharmaceuticae Universitatis Comenianae 2013;60:32-6. https://doi.org/10.2478/afpuc-2013-0006
  12. Dluholucky S, Knapkova M, Zahorcova M. First results from expanded newborn screening in Slovak Republic. Acta Facultatis Pharmaceuticae 2014;61:1-4.
  13. Hamawandi AMH, Rashid JA, Raof Saeed HHMH, Hawrami OM. Annual incidence of phenylketonuria in Sulaimani City. Merit Res J Med Med Sci 2015;3:427-31.
  14. Selim LA, Hassan SA, Salem F, Orabi A, Hassan FA, El-Mougy F, et al. Selective screening for inborn errors of metabolism by tandem mass spectrometry in Egyptian children: a 5 year report. Clin Biochem 2014;47:823-8. https://doi.org/10.1016/j.clinbiochem.2014.04.002
  15. Tada K, Tateda H, Arashima S, Sakai K, Kitagawa T, Aoki K, et al. Followup study of a nation-wide neonatal metabolic screening program in Japan. A collaborative study group of neonatal screening for inborn errors of metabolism in Japan. Eur J Pediatr 1984;142:204-7. https://doi.org/10.1007/BF00442450
  16. Ozalp I, Coskun T, Tokatli A, Tokol S, Ozguc M, Koksal G, et al. Neonatal PKU screening in Turkey: 7 years experience in a developing country. Screening 1995;4:139-47. https://doi.org/10.1016/0925-6164(95)00125-5
  17. Senemar S, Ganjekarimi H, Fathzadeh M, Senemar S, Tarami B, Bazrgar M. Epidemiological and clinical study of phenylketonuria (PKU) disease in the national screening program of neonates, Fars Province, Southern Iran. Iran J Public Health 2009;38:58-64.
  18. Munn Z, Moola S, Lisy K, Riitano D. Joanna Briggs Institute reviewer's manual. Adelaide: The Joanna Briggs Institute, 2017.
  19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135
  20. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934-9. https://doi.org/10.1016/j.jclinepi.2011.11.014
  21. Al-Jasmi FA, Al-Shamsi A, Hertecant JL, Al-Hamad SM, Souid AK. Inborn errors of metabolism in the United Arab Emirates: disorders detected by newborn screening (2011-2014). JIMD Rep 2016;28:127-35.
  22. Farhud DD, Kabiri M. Incidence of phenylketonuria (PKU) in Iran. Indian J Pediatr 1982;49:685-8. https://doi.org/10.1007/BF02752654
  23. Hitzeroth HW, Niehaus CE, Brill DC. Phenylketonuria in South Africa. A report on the status quo. S Afr Med J 1995;85:33-6.
  24. Zhong K, Wang W, He F, Wang Z. The status of neonatal screening in China, 2013. J Med Screen 2016;23:59-61. https://doi.org/10.1177/0969141315597715
  25. MaCcready RA, Hussey MG. Newborn phenylketonuria detection program in Massachusetts. Am J Public Health Nations Health 1964;54:2075-81. https://doi.org/10.2105/AJPH.54.12.2075
  26. Peterson RM, Koch R, Schaeffler GE, Wohlers A, Acosta PB, Boyle D. Phenylketonuria. Experience at one center in the first year of screening in California. Calif Med 1968;108:350-4.
  27. Fox JG, Hall DL, Haworth JC, Maniar A, Sekla L. Newborn screening for hereditary metabolic disorders in Manitoba, 1965-1970. Can Med Assoc J 1971;104:1085-8.
  28. Antonozzi I, Santagata G, Tofani R. Multiple neonatal screening for aminoacidopathies by ion exchange chromatography. Ric Clin Lab 1982;12:507-15.
  29. Liu SR, Zuo QH. Newborn screening for phenylketonuria in eleven districts. Chin Med J (Engl) 1986;99:113-8.
  30. Mathias D, Bickel H. Follow-up study of 16 years neonatal screening for inborn errors of metabolism in West Germany. Eur J Pediatr 1986;145:310-2. https://doi.org/10.1007/BF00439408
  31. Ozalp I, Coskun T, Ceyhan M, Tokol S, Oran O, Erdem G, et al. Incidence of phenylketonuria and hyperphenylalaninaemia in a sample of the Turkish newborn population. J Inherit Metab Dis 1986;9(Suppl 2):237-9. https://doi.org/10.1007/BF01799716
  32. Missiou-Tsagaraki S, Soulpi K, Loumakou M. Phenylketonuria in Greece: 12 years' experience. J Ment Defic Res 1988;32( Pt 4):271-87.
  33. Chen RG, Pan XS, Qian DL, Guo H. Twenty-one cases of phenylketonuria out of 358,767 newborns in Shanghai, China. J Inherit Metab Dis 1989;12:485. https://doi.org/10.1007/bf01802047
  34. Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. BMJ 1991;303:333-5. https://doi.org/10.1136/bmj.303.6798.333
  35. Gerasimova NS, Samutin AA, Steklova IV, Tuuminen T. Phenylketonuria screening in Moscow using a microplate fluorometric method. Screening 1992;1:27-35. https://doi.org/10.1016/0925-6164(92)90027-3
  36. Cabalska B, Nowaczewska I, Duczynska N, Laskowska-Klita T. Twentyfive years experience with newborn screening for phenylketonuria (PKU) in Poland. Screening 1993;2:29-32. https://doi.org/10.1016/0925-6164(93)90015-B
  37. Fernandez-Iglesias C, Florez IG, Rodriguez-Gonzalez MC, Gascon S. Neonatal screening for phenylketonuria and congenital hypothyroidism in Principado de Asturias (Spain) using two types of blood samples. Screening 1995;4:131-8. https://doi.org/10.1016/0925-6164(95)00119-0
  38. Kucinskas V, Jurgelevicius V, Cimbalistiene L, Jusciene D, Smirnova M, Zamkauskiene D. Management and results of mass neonatal screening in Lithuania. Acta Medica Lithuanica 1996;3:38-42.
  39. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001; 47:1945-55. https://doi.org/10.1093/clinchem/47.11.1945
  40. Schulze A, Mayatepek E, Hoffmann GF. Evaluation of 6-year application of the enzymatic colorimetric phenylalanine assay in the setting of neonatal screening for phenylketonuria. Clin Chim Acta 2002;317:27-37. https://doi.org/10.1016/S0009-8981(01)00736-7
  41. Capistrano-Estrada S, Padilla CD. Hyperphenylalaninemia in the Philippines. Southeast Asian J Trop Med Public Health 2003;34 Suppl 3:182-4.
  42. Charoensiriwatana W, Janejai N, Boonwanich W, Krasao P, Chaisomchit S, Waiyasilp S. Neonatal screening program in Thailand. Southeast Asian J Trop Med Public Health 2003;34 Suppl 3:94-100.
  43. Jiang J, Ma X, Huang X, Pei X, Liu H, Tan Z, et al. A survey for the incidence of phenylketonuria in Guangdong, China. Southeast Asian J Trop Med Public Health 2003;34 Suppl 3:185.
  44. Yoon HR, Lee KR, Kang S, Lee DH, Yoo HW, Min WK, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta 2005;354:167-80. https://doi.org/10.1016/j.cccn.2004.11.032
  45. Habib A, Fallahzadeh MH, Kazeroni HR, Ganjkarimi AH. Incidence of phenylketonuria in Southern Iran. Iran J Med Sci 2010;35:137-9.
  46. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010;33(Suppl 2):S295-305.
  47. Sutivijit Y, Banpavichit A, Wiwanitkit V. Prevalence of neonatal hypothyroidism and phenylketonuria in Southern Thailand: A 10-year report. Indian J Endocrinol Metab 2011;15:115-7. https://doi.org/10.4103/2230-8210.81941
  48. Alkhazrajy LA, Hassan AA. Overview of neonatal screening program applied at primary health care centers in Baghdad/Iraq. Int J Community Coop Stud 2016;4:46-64.
  49. Hassan FA, El-Mougy F, Sharaf SA, Mandour I, Morgan MF, Selim LA, et al. Inborn errors of metabolism detectable by tandem mass spectrometry in Egypt: The first newborn screening pilot study. J Med Screen 2016; 23:124-9. https://doi.org/10.1177/0969141315618229
  50. Saadatpour Y, Dehghan F, Rasekhi S, Zolghadri N. Incidence of neonatal phenylketonuria in hormozgan province, Southern Iran, 2014-2016. J Global Pharm Technol 2016;12:509-14.
  51. Abbaskhanian A, Zamanfar D, Afshar P, Asadpoor E, Rouhanizadeh H, Jafarnia A, et al. Incidence of neonatal hyperphenylalaninemia based on high-performance liquid chromatography confirmatory technique in Mazandaran Province, Northern Iran (2007-2015). Int J Prev Med 2017;8:93.
  52. Alfadhel M, Al Othaim A, Al Saif S, Al Mutairi F, Alsayed M, Rahbeeni Z, et al. Expanded Newborn Screening Program in Saudi Arabia: Incidence of screened disorders. J Paediatr Child Health 2017;53:585-91. https://doi.org/10.1111/jpc.13469
  53. Ounap K, Lillevali H, Metspalu A, Lipping-Sitska M. Development of the phenylketonuria screening programme in Estonia. J Med Screen 1998;5:22-3. https://doi.org/10.1136/jms.5.1.22
  54. Alm J, Larsson A. Evaluation of a nation-wide neonatal metabolic screening programme in Sweden 1965-1979. Acta Paediatr Scand 1981;70:601-7. https://doi.org/10.1111/j.1651-2227.1981.tb05753.x
  55. Aoki K, Wada Y. Outcome of the patients detected by newborn screening in Japan. Acta Paediatr Jpn 1988;30:429-34. https://doi.org/10.1111/j.1442-200X.1988.tb02533.x
  56. Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, de Baulny HO, et al. Neonatal screening and long-term follow-up of phenylketonuria: the French database. Early Hum Dev 2001;65:149-58. https://doi.org/10.1016/S0378-3782(01)00223-7
  57. Zaffanello M, Zamboni G, Tato L. Neonatal screening program for inborn errors of metabolism: a retrospective study from 1978 to 1997 in Northeastern Italy. Ita J Pediatr 2002;28:479-83.
  58. Cornejo V, Raimann E, Cabello JF, Valiente A, Becerra C, Opazo M, et al. Past, present and future of newborn screening in Chile. J Inherit Metab Dis 2010;33 Suppl 3:S301-6.
  59. Vilarinho L, Rocha H, Sousa C, Marcao A, Fonseca H, Bogas M, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis 2010;33 Suppl 3:S133-8.
  60. Shi XT, Cai J, Wang YY, Tu WJ, Wang WP, Gong LM, et al. Newborn screening for inborn errors of metabolism in mainland china: 30 years of experience. JIMD Rep 2012;6:79-83. https://doi.org/10.1007/8904_2011_119
  61. Yang LL, Mao HQ, Zhang WF, Zhao ZY, Yang RL, Zhou XL, et al. Pitfalls in the management of phenylketonuria in China. HK J Paediatr 2012;17:143-7.
  62. Al Hosani H, Salah M, Osman HM, Farag HM, El-Assiouty L, Saade D, et al. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. East Mediterr Health J 2014;20:17-23. https://doi.org/10.26719/2014.20.1.17
  63. Ramalho AR, Ramalho RJ, Oliveira CR, Magalhaes MM, Santos EG, Sarmento PM, et al. Evaluation of effectiveness and outcome of PKU screening and management in the State of Sergipe, Brazil. Arq Bras Endocrinol Metabol 2014;58:62-7. https://doi.org/10.1590/0004-2730000002885
  64. Pangkanon S, Charoensiriwatana W, Janejai N, Boonwanich W, Chaisomchit S. Detection of phenylketonuria by the newborn screening program in Thailand. Southeast Asian J Trop Med Public Health 2009;40:525-9.
  65. Schuler A, Somogyi C, Toros I, Nagy A, Kiss E, Varadi I, et al. Twenty years of experience with phenylketonuria in Hungary. Int Pediatr 1996;11:114-7.
  66. Ounap K, Lillevali H, Klaassen T, Metspalu A, Sitska M. The incidence and characterization of phenylketonuric patients in Estonia. J Inherit Metab Dis 1996;19:381-2. https://doi.org/10.1007/bf01799278
  67. Pangkanon S, Ratrisawadi V, Charoensiriwatana W, Techasena W, Boonpuan K, Srisomsap C, et al. Phenylketonuria detected by the neonatal screening program in Thailand. Southeast Asian J Trop Med Public Health 2003;34 Suppl 3:179-81.

피인용 문헌

  1. 25 Hydroxy Vitamin D Level, Bone Health, Vitamin D and Calcium Intake in Chilean Patients with Phenylketonuria and Hyperphenylalaninemias vol.9, 2021, https://doi.org/10.1590/2326-4594-jiems-2021-0004
  2. Nitrogen Balance after the Administration of a Prolonged-Release Protein Substitute for Phenylketonuria as a Single Dose in Healthy Volunteers vol.13, pp.9, 2020, https://doi.org/10.3390/nu13093189
  3. Telehealth and COVID-19: Empowering Standards of Management for Patients Affected by Phenylketonuria and Hyperphenylalaninemia vol.9, pp.11, 2020, https://doi.org/10.3390/healthcare9111407
  4. Birth prevalence of phenylalanine hydroxylase deficiency: a systematic literature review and meta-analysis vol.16, pp.1, 2021, https://doi.org/10.1186/s13023-021-01874-6